XANAX XR Tablets are indicated for the treatment of panic disorder, with or without agoraphobia.
XANAX XR Indication and Important Safety Information
Please scroll to see the Indication below.
Important Safety Information
XANAX XR is contraindicated in patients with known sensitivity to this drug or other benzodiazepines, in patients with acute narrow-angle glaucoma, and in patients taking potent CYP3A inhibitors, such as ketoconazole and itraconazole.
Certain adverse clinical events are a direct consequence of physical dependence to alprazolam. These include a spectrum of discontinuation symptoms, the most important being the possibility of seizure.
The most commonly observed adverse events in patients treated with XANAX XR in controlled clinical trials (≥5% and at least twice the incidence observed for placebo) were: sedation (45.2% vs 22.6%), somnolence (23.0% vs 6.0%), memory impairment (15.4% vs 6.9%), dysarthria (10.9% vs 2.6%), abnormal coordination (9.4% vs 0.9%), ataxia (7.2% vs 3.2%), and decreased libido (6.0% vs 2.3%).
Indication
XANAX XR Tablets are indicated for the treatment of panic disorder, with or without agoraphobia.
Please see full prescribing information.